NCT06333821View on ClinicalTrials.gov

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2030

Study Completion Date

April 1, 2030

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Nimotuzumab

Nimotuzumab 400mg

DRUG

Cisplatin

Cisplatin 40mg/m\^2

RADIATION

External Beam Radiotherapy (EBRT)

External Beam Radiotherapy (EBRT)

RADIATION

Brachytherapy

Brachytherapy

DRUG

placebo for Nimotuzumab

placebo for Nimotuzumab 400mg

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER